GlassScriptPhysician profile
Michael F Sheehan
NPI 1528060597
$12,708.86
in general payments reported to CMS, 2019-2025
44 companies · $1,852 in 2025
The $1,852 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,549 · 2020: $1,068 · 2021: $1,403 · 2022: $1,853 · 2023: $2,035 · 2024: $1,948 · 2025: $1,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,744 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,743.88 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,277.62 | 2019-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,273.21 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,215.85 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Abbvie INC. | $741.97 | 2020-2025 | Vraylar |
| Alkermes, INC. | $733.54 | 2021-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $724.96 | 2019-2022 | |
| Axsome Therapeutics, INC. | $682.58 | 2022-2025 | Auvelity, Sunosi |
| Indivior INC. | $673.63 | 2019-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $640.36 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $521.49 | 2021-2025 | Caplyta |
| Lundbeck LLC | $491.83 | 2019-2025 | Rexulti |
| Noven Therapeutics, LLC | $479.84 | 2023-2025 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $399.49 | 2021-2022 | |
| Eisai INC. | $399.24 | 2020-2021 | |
| Almatica Pharma LLC | $318.77 | 2021-2025 | Loreev Xr, Gralise |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sheehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.